[1]
|
Y. Ma and R. M. Pope, “The Role of Macrophages in Rheumatoid Arthritis,” Current Pharmaceutical Design, Vol. 11, No. 5, 2005, pp. 569-580.
doi:10.2174/1381612053381927
|
[2]
|
R. W. Kinne, B. Stuhlmüller and G. R. Burmester, “Cells of the Synovium in Rheumatoid Arthritis: Macrophages,” Arthritis Research and Therapy, Vol. 9, 2007, p. 224.
doi:10.1186/ar2333
|
[3]
|
D. Mulherin, O. Fitzgerald and B. Bresnihan, “Synovial Tissue Macrophage Populations and Articular Damage in Rheumatoid Arthritis,” Arthritis and Rheumatism, Vol. 39, No. 1, 1996, pp. 115-124. doi:10.1002/art.1780390116
|
[4]
|
B. A. Zabel, W. W. Agace, J. J. Campbell, H. M. Heath, D. Parent, A. I. Roberts, E. C. Ebert, N. Kassam, S. Qin, M. Zovko, G. J. LaRosa, L. L. Yang, D. Soler, E. C. Butcher, P. D. Ponath, C. M. Parker and D. P. Andrew, “Human G Protein-Coupled Receptor GPR-9-6/CC Chemokine Receptor 9 Is Selectively Expressed on Intestinal homing T Lymphocytes, Mucosal Lymphocytes, and Thymocytes and Is Required for Thymus-Expressed Chemokine-Mediated Chemotaxis, Journal of Experimental Medicine, Vol. 190, No. 9, 1999, pp. 1
|
[5]
|
E. J. Kunkel, J. J. Campbell, G. Haraldsen, J. Pan, J. Boisvert, A. I. Roberts, E. C. Ebert, M. A. Vierra, S. B. Goodman, M. C. Genovese, A. J. Wardlaw, H. B. Greenberg, C. M. Parker, E. C. Butcher, D. P. Andrew and W. W. Agace, “Lymphocyte CC Chemokine Receptor 9 and Epithelial Thymus-Expressed Chemokine (TECK) expression Distinguish the Small Intestinal Immune Compartment: Epithelial Expression of Tissue-Specific Chemokines as an Organizing Principle in Regional Immunity,” Journal of Experimental Medicine
|
[6]
|
Z. Qiuping, L. Qun, H. Chunsong, Z. Xiaolian, H. Baojun, Y. Mingzhen, L. Chengming, H. Jinshen, G. Qingping, Z. Kejian, S. Zhimin, Z. Xuejun, L. Junyan and T. Jinquan, “Selectively Increased Expression and Functions of Chemokine Receptor CCR9 on CD4+ T cells from Patients with T-Cell Lineage Acute Lymphocytic Leukaemia,” Cancer Research, Vol. 63, No. 19, 2003, pp. 6469-6477.
|
[7]
|
F. F. Amersi, A. M. Terando, Y. Goto, R. A. Scolyer, J. F. Thompson, A. N. Tran, M. B. Faries, D. L. Morton and D. S. Hoon, “Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine,” Clinical Cancer Research, Vol. 14, 2008, pp. 638-645. doi:10.1158/1078-0432.CCR-07-2025
|
[8]
|
S. Singh, U. P. Singh, J. K. Stiles, W. E. Grizzle and J. W. Lillard Jr., “Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion,” Clinical Cancer Research, Vol. 18, No. 21, 2004, pp. 8743-8750.
doi:10.1158/1078-0432.CCR-04-0266
|
[9]
|
E. L. Johnson, R. Singh, S. Singh, C. M. Johnson-Holiday, W. E. Grizzle, E. E. Partridge and J. W. Lillard Jr., “CCL25-CCR9 Interaction Modulates Ovarian Cancer Cell Migration, Metalloproteinase Expression, and Invasion,” World Journal of Surgical Oncology, Vol. 8, 2010, p. 62. doi:10.1186/1477-7819-8-62
|
[10]
|
C. Johnson-Holiday, R. Singh, E. Johnson, S. Singh, C. R. Stockard, W. E. Grizzle and J. W. Lillard Jr., “CCL25 Mediates Migration, Invasion and Matrix Metalloproteinase Expression by Breast Cancer Cells in a CCR9-Dependent Fashion,” International Journal of Oncology, Vol. 38, No. 5, 2011, pp. 1279-1285.
|
[11]
|
B. Eksteen and D. H. Adams, “GSK-1605786, a Selective Small-Molecule Antagonist of the CCR9 Chemokine Receptor for the Treatment of Crohn’s Disease,” IDrugs, Vol. 13, No. 7, 2010, pp.472-781.
|
[12]
|
M. J. Walters, Y. Wang, N. Lai, T. Baumgart, B. N. Zhao, D. J. Dairaghi, P. Bekker, L. S. Ertl, M. E. Penfold, J. C. Jaen, S. Keshav, E. Wendt, A. Pennell, S. Ungashe, Z. Wei, J. J. Wright and T. J. Schall, “Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease,” Journal of Pharmacology and Ex- perimental Therapeutics, Vol. 335, No. 1, 2010, pp. 61-69. doi:10.1124/jpet.110.169714
|
[13]
|
C. Schmutz, A. Cartwright, H. Williams, O. Haworth, J. H. Williams, A. Filer, M. Salmon, C. D. Buckley and J. Middleton, “Monocytes/Macrophages Express CCR9 in Rheumatoid Arthritis and CCL25 Stimulates Their Differentiation,” Arthritis Research and Therapy, Vol. 12, No. 4, 2010, pp. R161. doi:10.1186/ar3120
|
[14]
|
D. Brackertz, G. F. Mitchell and I. R. Mackay, “Anti- gen-Induced Arthritis in Mice,” Arthritis and Rheumatism, Vol. 20, No. 3, 1977, pp. 841-850.
doi:10.1002/art.1780200314
|
[15]
|
W. B. van den Berg, L. A. Joosten and P. L. van Lent, “Murine Antigen-Induced Arthritis,” Methods in Mole- cular Medicine, Vol. 136, No. 2, 2007, pp.243-253.
doi:10.1007/978-1-59745-402-5_18
|
[16]
|
M. A. Nowell, P. J. Richards, S. Horiuchi, N. Yamamoto, S. Rose-John, N. Topley, A. S. Williams and S. A. Jones, “Soluble IL-6 Receptor Governs IL-6 Activity in Expe- rimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein,” Journal of Immunology, Vol. 171, 2003, pp. 3202-3209.
|
[17]
|
A. Mantovani, A. Sica and M. Locati, “New Vistas on Macrophage Differentiation and Activation,” European Journal of Immunology, Vol. 37, No. 1, 2007, pp.14-16.
doi:10.1002/eji.200636910
|
[18]
|
M. Corr and B. Crain, “The Role of FcgammaR Signaling in the K/B × N Serum Transfer Model of Arthritis,” Journal of Immunology, Vol. 169, No. 11, 2002, pp. 6604-6609.
|
[19]
|
J. P. Jacobs, A. Ortiz-Lopez, J. J. Campbell, C. J. Gerard, D. Mathis and C. Benoist, “Deficiency of CXCR2, but Not Other Chemokine Receptors, Attenuates a Murine Model of Autoantibody-Mediated Arthritis,” Arthritis and Rheumatism, Vol. 62, No. 7, 2010, pp.1921-1932.
|
[20]
|
N. Nakamoto, H. Ebinuma H, T. Kanai, P. S. Chu, Y. Ono, Y. Mikami, K. Ojiro, M. Lipp, P. E. Love, H. Saito and T. Hibi, “CCR9(+) Macrophages Are Required for Acute Liver Inflammation in Mouse Models of Hepatitis,” Gastroenterology, Vol. 142, No. 2, 2012, pp.366-376.
doi:10.1053/j.gastro.2011.10.039
|
[21]
|
B. Johansson-Lindbom and W. W. Agace, “Generation of Gut-Homing T Cells and Their Localization to the Small Intestinal Mucosa,” Immunological Reviews, Vol. 215, 2007, pp. 226-242.
doi:10.1111/j.1600-065X.2006.00482.x
|
[22]
|
K. A. Papadakis, J. Prehn, S. T. Moreno, L. Cheng, E. A. Kouroumalis, R. Deem, T. Breaverman, P. D. Ponath, D. P. Andrew, P. H. Green, M. R. Hodge, S. W. Binder and S. R. Targan, “CCR9-Positive Lymphocytes and Thymus-Expressed Chemokine Distinguish Small Bowel from Colonic Crohn’s Disease,” Gastroenterology, Vol. 121, No. 2, 2001, pp.246-254. doi:10.1053/gast.2001.27154
|
[23]
|
C. Koenecke and R. F?rster, “CCR9 and Inflammatory Bowel Disease,” Expert Opinion on Therapeutic Targets, Vol. 13, No. 3, 2009, pp.297-306.
doi:10.1517/14728220902762928
|
[24]
|
M. Apostolaki, M. Manoloukos, M. Roulis, M. A. Wurbel, and W. Müller, “Role of β7 Integrin and the Chemokine/Chemokine Receptor Pair CCL25/CCR9 in Modelled TNF-Dependent Crohn’s Disease,” Gastroenterology, Vol. 134, No. 7, 2008, pp. 2025-2035.
doi:10.1053/j.gastro.2008.02.085
|
[25]
|
M. A. Wurbel, M. Malissen, D. Guy-Grand, E. Meffre, M. C. Nussenzweig, M. Richelme, A. Carrier and B. Malissen, “Mice Lacking the CCR9 CC-Chemokine Receptor Show a Mild Impairment of Early T-and B-Cell Development and a Reduction in T-Cell Receptor Gammadelta(+) Gut Intraepithelial Lymphocytes,” Blood, Vol. 98, No. 9, 2001, pp. 2626-2632.
doi:10.1182/blood.V98.9.2626
|